Provided by Tiger Trade Technology Pte. Ltd.

LUYE PHARMA

1.895
+0.0703.84%
Volume:23.19M
Turnover:43.41M
Market Cap:7.57B
PE:10.22
High:1.895
Open:1.815
Low:1.815
Close:1.825
52wk High:3.690
52wk Low:1.690
Shares:4.00B
HK Float Shares:4.00B
Volume Ratio:1.04
T/O Rate:0.58%
Dividend:- -
Dividend Rate:- -
EPS(LYR):0.186
ROE:4.27%
ROA:2.18%
PB:0.42
PE(LYR):10.22
PS:1.06

Loading ...

绿叶制药(02186)2025年年报:营收63.084亿元,净利同比增9.4%,深耕四大治疗领域

Bulletin Express
·
Apr 29

Shandong Boan Biotech publishes 2025 annual report

Reuters
·
Apr 29

Luye Pharma publishes 2025 annual report

Reuters
·
Apr 29

Shandong Boan Bio proposes H-share restricted share unit incentive scheme

Reuters
·
Apr 28

Shandong Boan says China CDE accepts Phase II trial application for BA1106-BA1104 combo in NSCLC

Reuters
·
Apr 26

Luye Pharma launches first U.S. pharmacokinetic study for dual-acting VMAT2/Sigma-1R candidate LY03015

Bulletin Express
·
Apr 20

LUYE PHARMA's Innovative Drug LY03015 Enrolls First Patient in US Pharmacokinetic Bridging Study

Stock News
·
Apr 20

Luye Pharma enrolls first subject in US PK bridging trial of LY03015

Reuters
·
Apr 20

Luye Pharma Enrolls First Patient in Phase 2 China Trial of Alzheimer's Psychosis Drug

MT Newswires Live
·
Apr 16

CATL Reports 48.52% Surge in Q1 Net Profit to RMB 20.74 Billion

Stock News
·
Apr 16

LUYE PHARMA's Innovative Drug LY03017 Enrolls First Patient in Chinese Phase II Trial for Alzheimer's Disease Psychosis

Stock News
·
Apr 15

Luye Pharma initiates China Phase II trial of LY03017 targeting Alzheimer’s disease-related psychosis

Bulletin Express
·
Apr 15

A Look At Luye Pharma Group (SEHK:2186) Valuation As LY03020 Enters Phase II For Schizophrenia

Simply Wall St.
·
Apr 15

LUYE PHARMA Shares Climb Nearly 3% in Morning Session as Self-Developed Drug LY03020 Enrolls First Patient in Chinese Phase II Trial

Stock News
·
Apr 14

UBS Increases Stake in LUYE PHARMA by 13.95 Million Shares at HK$2.85 Each

Stock News
·
Apr 13

LUYE PHARMA's Innovative Drug LY03020 Enrolls First Patient in Chinese Phase II Trial

Stock News
·
Apr 08

Luye Pharma enrolls first patient in China Phase II trial of LY03020 schizophrenia drug

Reuters
·
Apr 08

Luye Pharma Maintains Stable Share Base in March 2026; USD 180 Million Convertible Bonds Allow Up to 288.79 Million New Shares

Bulletin Express
·
Apr 08

Undiscovered Gems In Asia Including 3 Promising Small Cap Stocks

Simply Wall St.
·
Apr 06

Luye Pharma Group (SEHK:2186) Valuation After Earnings Growth And Surprise 2025 Dividend Decision

Simply Wall St.
·
Apr 04